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Abstract Alzheimer’s disease (AD) is a progressive
neurological disorder that mostly affects the elderly pop-
ulation. Learning and memory impairment as the most
characteristic manifestation of dementia could be induced
chemically by scopolamine, a cholinergic antagonist.
Cholinergic neurotransmission mediated brain oxidative
stress. Citrus aurantium (CA) has traditionally been used
for the treatment of insomnia, anxiety and epilepsy. The
present study was designed to investigate the effect of
Citrus aurantium on scopolamine-induced learning and
memory deficit in rats. Forty-two Wistar rats were divided
into six equal groups. (1) Control (received saline), (2)
SCOP (scopolamine at a dose of 1 mg/kg for 15 days), (3)
and (4) SCOP ? CA (scopolamine and CA extract at doses
of 300 and 600 mg/kg per day for 15 days), (5) and (6)
intact groups (CA extract at 300 and 600 mg/kg per day for
15 days, respectively). Administration of CA flower extract
significantly restored memory and learning impairments
induced by scopolamine in the passive avoidance test and
also reduced escape latency during trial sessions in the
Morris water maze test. Citrus aurantium flower extract
significantly decreased the serum malondialdehyde (MDA)
levels. Citrus aurantium flower extract has repairing effects
on memory and behavioral disorders produced by scopol-
amine and may have beneficial effects in the treatment of
AD.
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Introduction
Alzheimer’s disease usually leads to a progressive memory
loss and causes cognitive and behavioral impairments [1].
Alzheimer’s disease is known to be related to excessive
neuronal loss, decrease in acetylcholine level, increased
inflammation and oxidative stress [2].
Cholinergic deficits are consistently associated with
memory and learning loss as well as the severity of Alz-
heimer’s disease [3].
Impairments of learning and memory, can be induced
chemically in experimental animals by scopolamine [4].
Scopolamine is a blocker of muscarinic acetylcholine
receptor that serves as a beneficial pharmacological tool in
producing a model of amnesia [4].
There is notable evidence that scopolamine causes oxi-
dative stress through the interference with acetylcholine in
brain leading to cognitive impairment [5].
Brain oxidative stress was reported following the
intra ventricular administration of ethylcholine aziridi-
nium, a toxic analog of choline that disrupts high-
affinity choline transport producing a persistent pre-
synaptic cholinergic hypofunction with the induction of
amnesia [5].
Decreased numbers of [3H] N-methyl scopolamine
binding sites were observed in the presence of high con-
centrations of H2O2 as an inducer of lipid peroxidation in
rat cerebral cortex membranes [6].
Cholinergic nerve stimulation in basal forebrain and
hippocampus was reported to be excitotoxic, causing
tonic–clonic convulsions due to the release of glutamate
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mediated through the production of ROS (reactive oxygen
species) [7].
The brain and nervous system are considered to be more
susceptible to peroxidative damage than other tissues due
to their high content of polyunsaturated lipid, high oxygen
utilization and low antioxidative enzymes [8].
Although the mechanisms of the anti-amnesic effects of
most herbal extracts and constituents are not yet fully
understood, one or more of the effective ingredients were
considered to activate the central Ach(Acetylcholine)
function through inhibition of AChE (acetylcholinesterase)
[9].
Citrus aurantium is among the species that have been
used for medicinal purposes [10]. In Iranian folk medicine,
the flowers of Citrus aurantium are used in the treatment of
neurological disorders such as hysteria, epilepsy and
neurasthenia [10].
Citrus aurantium has bioactive components such as
phenolics, flavonoids and vitamins. Linalool (59 %) and
linalyl acetate (23 %) constitute the major composition of
the essential oil of Citrus aurantium [11]. Previous studies
showed that Citrus aurantium plant had inhibitory effect on
acetylcholinesterase [12, 13].
In this study, we investigated whether the methanolic
extract of Citrus aurantium flowers could inhibit the
memory impairment induced by scopolamine through the
inhibition of AChE or decreased the oxidative stress. The
restored degree of impairment was gauged using both
passive avoidance and the Morris water maze tests with or
without treatment.
Methods
Preparation of the extract
Citrus aurantium flowers were milled, finely powdered and
extracted by 80 % methanol. This extract was filtered and
concentrated under reduced pressure on a rotary evaporator
and then lyophilized. The extract was dissolved in water
and stored at 4 C until use [10].
Measurement of antioxidant activity
Briefly, various concentrations of the extract were mixed
with DPPH (2,2-diphenyl-1-picrylhydrazyl) solution in
methanol. After 15 min at room temperature, the absor-
bance was recorded at 517 nm using a UV–Vis spectro-
photometer [14].
Inhibition of free radical by DPPH (%) was calculated
using the following formula
I %ð Þ ¼ 100  Acontrol  Asample
 
=Acontrol
Acontrol  A sample
Acontrol
Total phenolic compounds measurement
The amount of phenols was obtained based on mg/g in
gallic acid equivalent. The standard curve was plotted
using 12.5, 25, 50, 62.5, 100, and 125 mg/L solutions of
gallic acid in methanol and water (60:40, v/v) [14].
Total flavonoid and flavonol measurement
The amount of total flavonoids in the Citrus aurantium
extract was determined using the colorimetric method.
Solution with 1.5 mL of methanol (60 %), 1 mL of 2 %
aluminum chloride, and 6 mL of 5 % potassium acetate
was added to 1 mL of the Citrus aurantium extract. The
mixture was left at room temperature for 40 min. The
absorbance of the reaction mixture was then measured at
415 nm. The aluminum chloride colorimetric method was
employed for flavonol determination, but the incubation
period was 150 min and the absorbance of the reaction
mixture was determined at 440 nm. Total flavonoids and
flavonols were expressed in terms of rutin equivalent (mg/
g), which is a common reference compound [14].
Animals
Male Wistar rats, weighing 150–250 g and aged 3–4 months,
were obtained from Pasteur Institute (Tehran, Iran). Rats
were housed in cage (four per cage) at 25 C with a con-
trolled 12 h light–dark cycle. Food and water were freely
available. All experiments were executed in accordance with
the Guide for the Care and Use at Laboratory Animals and
were approved by Research and Ethics Committee of Med-
ical Sciences School of Shahrekord University.
Animals were randomly divided into the following six
groups of seven rats: (1) Control, received saline for
15 days via i.p injection, (2) scopolamine-treated group:
rats received scopolamine at a dose of 1 mg/kg for 15 days
via i.p injection (SCOP), (3) SCOP- CA 300 group, rats
received Citrus aurantium extract at 300 mg and scopol-
amine at 1 mg/kg for 15 days, (4) SCOP- CA 600 group,
rats received Citrus aurantium extract at 600 mg and
scopolamine at 1 mg/kg for 15 days, (5) and (6) intact
groups received Citrus aurantium extract at 300 and
600 mg/kg, respectively, for 15 days. Scopolamine (sigma,
USA) was dissolved in saline at final concentrations of
1 mg/kg. Administration of scopolamine and extract in
experimental groups was done before the start of
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behavioral testing and during behavioral testing. Following
the behavioral tests, under deep anesthesia the blood
sample collected from heart and the brains was quickly
removed. Different parts of the brains such as hippocam-
pus, cortex and subcortex (The Subcortex is located below
the cerebral cortex and completely covered by it. It can be
divided into three general areas: Brainstem or hindbrain;
midbrain; and forebrain) were separated.
Water maze test
A circular water pool (183 cm diameter and 60 cm deep)
was used for a water maze test [15]. A black escape plat-
form was placed into water and submerged 1 cm below the
water in one quadrant water maze surface. A platform was
located in the constant position, i.e., in the middle of one
quadrant (in our experiment, in zone 1) equidistant from
the center and edge of the pool. Rats were allowed to locate
the platform in a time span of up to 60 s. Rats that could
find the platform were allowed to stay on it for 15 s.
Animals were given four trials daily for four consecutive
days, with an inter trial interval of 10 min. On the fifth day,
rats were individually subjected to a probe trial session by
removing the platform and were allowed to swim for 60 s
to search for the platform.
Passive avoidance test
Passive avoidance test was carried out using a shuttle box
apparatus [14]. The apparatus consisted of a lighted com-
partment and a dark compartment with a grid floor. The two
compartments were separated by a guillotine door and each
had a grid floor through which a foot shock could be
delivered. This test was performed for each rat during the
4 days. On the first and second days of testing, each rat was
placed on the apparatus and left for 5 min to habituate to the
apparatus. On the third day, an acquisition trial was per-
formed. On the training day, the rat was placed in the lighted
compartment, facing away from the dark compartment and
allowed to explore for 20 s. After 20 s the guillotine door
was lifted. When the rat entered the dark compartment with
all four paws, the guillotine door was closed, and the latency
to enter was recorded. After the door was closed, a foot
shock (1 mA, 1 s duration) was delivered through the
stainless steel rods. All the animals that could enter in the
dark compartment within 60 s as in the training session
received a foot shock. On the fourth day (24 h after train-
ing), the rat was returned to the lighted compartment. After
5 s, the guillotine door was lifted. When the rat entered the
dark compartment, the guillotine door was closed, and the
step-through latency for animals was recorded.
Ferric reducing/antioxidant power (FRAP) assay
The antioxidant power of plasma was determined by
measuring its ability to reduce Fe3? to Fe2? with FRAP
(ferric reducing antioxidant power) test. FeSO4
(100–1,000 lM concentration range) was used as a stan-
dard in FRAP assay [14].
Measurement of plasma MDA
The optimized assay was carried out as follows: 50 ll
plasma or the standard was treated with 50 ll (0.05 %)
BHT (butylated hydroxytoluene), followed by the addition
of 400 ll H3PO4 (0.44 M) and 100 ll TBA (thiobarbituric
acid) (42 mM), vortexed and then incubated for 60 min at
100 C. The reaction was stopped by cooling at 4 C, then
250 ll of n-butanol was added for extraction of MDA–
TBA complex. The solution centrifuged for 5 min at
14,000 rpm to separate two phases. The supernatant (20 ll)
was injected into the HPLC system [14].
MDA levels of brain
Brain tissues were homogenized in ice-cold Tris–HCl
buffer (50 mM, pH 7.4) for 2 min at 5,000 rpm. The
homogenized solution was then centrifuged for 60 min at
5,000g.
The sample was mixed with two volumes of cold 10 %
(w/v) trichloroacetic acid to precipitate protein. The pre-
cipitate was pelleted by centrifugation and an aliquot of the
supernatant was reacted with an equal volume of 0.67 %
(w/v) TBA in a boiling water bath for 10 min. After
cooling, the absorbance was read at 532 nm using spec-
trophotometer [14].
AchE assay
Animals were sacrificed by decapitation and brain tissue
was immediately removed and placed in a solution of
250 mM sucrose, 100 mM Tris–HCl, pH 7.5, in an ice
bath. Brain tissue was then homogenized in a glass potter
in the same sucrose Tris–HCl solution (1:4 (w/v)). Ali-
quots of resulting brain homogenates were stored at
-80 C until utilization. Acetylcholinestrase activity was
measured by the method of Ellman [16]. A reaction
mixture contained 470 lL sodium phosphate (0.1 mM,
pH = 8), 167 lL (2-nitro benzoic acid) DTNB and 33 lL
homogenate was incubated for 5 min at 37 C. The ace-
tylcholine iodide (1 mM) 280 lL was added to reaction
mixture. The reaction was terminated by 50 lL neostig-
mine (2 mM).
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Statistical analysis
Data were expressed as mean ± SEM (standard error of
mean) and processed by commercially available software
SPSS 11.0. All results were compared using one-way
ANOVA and post hoc Tukey test. p value less than 0.05
was considered to be statistically significant.
Results
Standardization of Citrus aurantium flowers extract
Total amount of phenolic compounds in Citrus aurantium
flowers extract was 89 mg/g gallic acid equivalent per one
gram of dried extract. The total amounts of flavonoid and
flavonol compounds were 12.5 and 6 mg/g, respectively.
Radical scavenging activity of Citrus aurantium
flowers extract
IC50 values for radical scavenging activity of CA extract
are shown in Table 1. Citrus aurantium flower extract
showed free radical scavenging activity against DPPH
radicals, with an IC50 value of 320 lg/ml.
Passive avoidance response
The step-through latency (T2) of SCOP-treated rats was
significantly shorter than that of the control rats
(p = 0.001). CA extract administration at a dose of
300 mg/kg reversed the shorter step-through latency
induced by SCOP (p = 0.043). Furthermore, the step-
through latency (T2) time of intact rats treated with 300 mg/
kg of Citrus aurantium flowers extract significantly
increased compared to SCOP rats (p = 0.001) (Fig. 1).
T2 significantly increased in Intact300CA group com-
pared to the SCOP ? 600 CA (p = 0.031). T2 in Intact
300CA group significantly increased when compared with
Intact600CA group (p = 0.012).
T2 of intact rats that received extract at dose of 600 mg
significantly increased compared with control group
(p = 0.037).
Spatial memory and learning
SCOP-treated group spent significantly less time in the
correct quadrant (zone1) compared with control group in
the probe trail (p = 0.001). In the probe test
SCOP ? 600CA, intact 300CA and intact 600CA groups
Table 1 DPPH radical scavenging activities of CA extract
Sample Concentration
(lg/ml)
DPPH radical scavenging
activity inhibition (%)
IC50 (lg/ml)
CA flowers extract 100 13.4
150 24.9
200 33.5
250 41.55
300 45
350 56.5
400 64.7
450 70.56
500 75.7
Fig. 1 The initial latency and step-through latency in the passive
avoidance response. T1 initial latency, T2 step-through latency.
*p \ 0.05; ***p \ 0.01. SCOP vs. control, SCOP ? 300CA,
SCOP ? 600CA, Intact 300CA, Intact 600CA groups (n = 7). CA
Citrus aurantium, SCOP scopolamine
Fig. 2 The time spent in zone 1 during the probe trial. *p \ 0.05;
***p \ 0.01
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demonstrated a significant preference for the quadrant in
which the platform was located on the preceding day (zone
1) when compared with SCOP-treated group (p = 0.015,
p = 0.003, p = 0.011, respectively) (Fig. 2).
The escape latency of the SCOP group was significantly
longer by means of memory impairment than that of the
control group during trial sessions (p \ 0.05). The decrease
in the escape latency improved significantly on the third
day in control, SCOP ? 300CA and SCOP ? 600CA
when compared with SCOP group (p = 0.031, p = 0.021,
p = 0.048, respectively). The latency before reaching
platform on the fourth day significantly decreased in con-
trol, SCOP ? 300CA and SCOP ? 600CA when com-
pared with SCOP group (p = 0.001, p = 0.003,
p = 0.049, respectively) (Fig. 3).
The latency to reach platform in days 2, 3 and 4 sig-
nificantly decreased compared with day 1 in experimental
groups (p \ 0.05). The latency to reach platform signifi-
cantly decreased in day 4 compared with day 2 (p = 0.033)
in experimental groups (data not shown).
Citrus aurantium flowers extract at doses of 300 and
600 mg/kg/day in intact rats caused a slight reduction (not
significant, p [ 0.05) in the latency compared with the
control group (data not shown).
Plasma antioxidant level
Scopolamine treatment significantly decreased the plasma
antioxidant level compared to the control group
(p = 0.043). CA treatment significantly increased the
plasma antioxidant level in SCOP ? 600CA, intact 300CA
and intact 600CA groups when compared with SCOP
group (p = 0.002, p = 0.016, p = 0.009, respectively).
Citrus aurantium flowers extract at a dose of 300 mg had
no effect on SCOP-treated group (Fig. 4). Plasma antiox-
idant level in SCOP ? 600CA group significantly
increased compared to SCOP ? 300CA group
(p = 0.025). Data not shown.
Brain MDA levels
Scopolamine treatment lead to a significant increase in
MDA content of hippocampus, cortex and subcortex in
SCOP group (p = 0.048, p = 0.005, p = 0.001, respec-
tively). Treatment with 300 mg/kg of CA extract in
SCOP ? 300CA group significantly reduced MDA content
in hippocampus, cortex and subcortex when compared with
SCOP group (p = 0.007, p = 0.004, p = 0.001, respec-
tively). CA extract significantly reduced MDA level of
hippocampus, cortex and subcortex in SCOP ? 600CA
group when compared with SCOP group (p = 0.008,
p = 0.005, p = 0.001, respectively). CA extract treatment
at doses of 300 and 600 mg significantly decreased the
MDA levels of hippocampus, cortex and subcortex in intact
groups when compared with SCOP group (p \ 0.05)
(Fig. 5).
Plasma MDA level
In SCOP group, scopolamine treatment significantly
increased plasma MDA level when compared with control
group (p = 0.006). CA extract administration at doses of
300 and 600 mg/kg in SCOP ? 300CA and
SCOP ? 600CA groups significantly reduced plasma
MDA levels when compared with SCOP group (p = 0.003,
p = 0.005, respectively) (Fig. 6).
Fig. 3 Spatial learning in experimental groups *p \ 0.05;
***p \ 0.01
Fig. 4 Plasma antioxidant levels (FRAP) in experimental groups.
*p \ 0.05; ***p \ 0.01
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In the intact groups, administration of CA extract
resulted in a significant reduction in plasma MDA levels at
doses of 300 and 600 mg/kg/day when compared with
SCOP group (p = 0.001, p = 0.005, respectively) and
control group (p = 0.001, p = 0.003, respectively). There
were no significant differences between intact groups and
groups received extract and scopolamine.
Effect of Citrus aurantium extract on the AChE activity
Citrus aurantium flower extract at doses of 300 and
600 mg/kg significantly inhibited acetylcholinesterase
activity in hippocampus (p \ 0.05) as compared to control
rats (Table 2).
Discussion
AD is one of the most ordinary neurodegenerative diseases,
resulting in progressive dysfunction in the brain, which
proceeds from mild and moderate to severe stages and
gradually destroys the brain [1]. Brain aging is known to be
related to decrease in acetylcholine level, neuronal loss,
increased inflammation, and oxidative stress [1]. Hippo-
campal cholinergic neurotransmission possesses an
important function in the process of learning and memory,
which is influenced by effective drugs in this system [17].
Acetylcholinesterase modulates acetylcholine to proper
levels by degradation, thus, excessive AChE activity leads
to constant acetylcholine deficiency, causing memory and
cognitive impairments [18].
Acetylcholinesterase inhibitors are the most effective
pharmacotherapy for AD [17]. These compounds indirectly
elevate acetylcholine concentrations in the AD-affected
brain [17]. Scopolamine significantly increases AChE and
malondialdehyde (MDA) levels in the cortex and hippo-
campus. Scopolamine causes oxidative stress through the
interference with acetylcholine in brain leading to cogni-
tive impairment [5]. The cognitive-enhancing activity of
Citrus aurantium flowers extract on the scopolamine-
induced memory impairments in rat was investigated using
passive avoidance test, Morris water maze test and bio-
chemical assessments. The passive avoidance test is gen-
erally used to evaluate memory in three steps (learning
acquisition, memory retention, and the retrieval process)
[19]. Citrus aurantium flowers extract administration
reversed the shorter step-through latency induced by sco-
polamine. To confirm the effects of Citrus aurantium
flowers extract on other types of memory, we performed
the Morris water maze test on spatial learning and memory.
Rats treated with scopolamine showed more prolonged
escape latency than rats treated with saline from the control
group. Citrus aurantium flowers extract treatment signifi-
cantly reduced escape latency in experimental groups
which suggested that long-term and working memory were
impaired by scopolamine. In addition, during the probe
trial session, the scopolamine-induced reduction in swim-
ming times within the platform quadrant was significantly
Fig. 5 Brain malondialdehyde level (MDA) in experimental groups.
*p \ 0.05; ***, €€€p \ 0.01
Fig. 6 Plasma MDA level in experimental groups. ***p \ 0.01
Table 2 Effects of CA extract on AChE activity in hippocampus of
the brain
Groups of rats Hippocampus (OD value/mg protein)
Control 0.1090 ± 0.010
300 mg CA 0.0823 ± 0.012*
600 mg CA 0.0608 ± 0.027*
OD optical density, CA Citrus aurantium
* p \ 0.05
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ameliorated by Citrus aurantium flowers extract, indicating
a positive effect on spatial learning and memory. In our
study, to further elucidate the mechanism of anti-amnesic
activity of Citrus aurantium flowers extract, lipid peroxi-
dation and AchE in the brain tissue were measured fol-
lowing the behavioral test. Citrus aurantium flowers
extract has potent inhibitory effect on AchE in brain tissue.
Our results showed that treatment with Citrus aurantium
flowers extract significantly decreased MDA levels of
serum and brain tissue in intact and scopolamine-treated
rats compared to the scopolamine-treated group.
Besides reducing cholinergic activity, oxidative stress
also plays an important role and is one of the major causes
for memory loss in AD [1]. Oxidative stress is produced by
free radicals, i.e., reactive oxygen species (ROS) generated
by oxygen and nitrogen-based molecules that have
unpaired electrons. Oxidative damage to the cellular
components results in alteration of the membrane proper-
ties such as fluidity, ion transport, enzyme activities, and
protein cross-linking [9]. Excessive oxidative damage
eventually results in cell death. Normally, biological
effects of free radicals in the body are controlled with
adequate antioxidants and antioxidant enzymes [9]. Our
results suggest that the Citrus aurantium flowers extract
reduced oxidative stress by reducing lipid peroxidation.
Nobiletin, a citrus poly methoxylated flavone that can
pass through the blood–brain-barrier, has a potential ther-
apeutic benefit for dementia including Alzheimer’s disease.
Nobiletin reverses the N-Methyl-D-aspartate receptor
antagonist dizocilpine-impaired memory by activating
extracellular signal-regulated kinase signaling in the hip-
pocampus of mice [20].
Naringin, a well-known flavanone glycoside of Citrus,
possesses antioxidant, anti-inflammatory, anti-apoptotic,
anti-osteoporosis and anti-carcinogenic properties [21].
Citrus aurantium at dose of 1 g/kg was able to enhance
the sleeping-time duration induced by pentobarbital in
adult male Swiss mice [22]. The cognition-enhancing
agents activate cholinergic transmission via an agonistic or
antagonistic effect on GABAA/benzodiazepine receptor
and GABAA/benzodiazepine receptor complex controls
acetylcholine release [23].
This study evaluated whether such impaired cognition
by scopolamine is associated with altered oxidative stress
indices. Our study indicated that improved learning and
memory in scopolamine-treated memory impairments in
rats may be related to decrease in oxidative stress in brain.
Our results suggested that the anti-amnesic effect of
Citrus aurantium flowers extract on scopolamine-induced
memory impairment may be related to the antioxidant
activity of extract or mediation of the cholinergic nervous
system.
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